Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21163968 | 0.76 | ACE (0.57) | TSHRALDH1A1 | |
| SCHEMBL5743117 | 0.76 | ACE (0.57) | TSHRALDH1A1 | |
| SCHEMBL5743122 | 0.76 | ACE (0.57) | TSHRALDH1A1 | |
| SCHEMBL21163843 | 0.76 | ACE (0.57) | TSHRALDH1A1 | |
| SCHEMBL15730093 | 0.75 | GAA (0.64) | TSHRALDH1A1GAAHSD11B1HPGD | |
| SCHEMBL6185241 | 0.75 | GAA (0.48) | TSHRALDH1A1GAAHSD11B1HPGD | |
| SCHEMBL15730586 | 0.75 | GAA (0.64) | TSHRALDH1A1GAAHSD11B1HPGD | |
| SCHEMBL6185245 | 0.75 | GAA (0.64) | TSHRALDH1A1GAAHSD11B1HPGD | |
| SCHEMBL21163185 | 0.75 | ALDH1A1 (0.48) | TSHRALDH1A1GAAHSD11B1HPGD | |
| SCHEMBL21696767 | 0.75 | ALDH1A1 (0.48) | TSHRALDH1A1GAAHSD11B1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11333974-B2 | Onium salt, chemically amplified resist composition, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20200133122-A1 | NOVEL ONIUM SALT, CHEMICALLY AMPLIFIED RESIST COMPOSITION, AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11333974-B2 | Onium salt, chemically amplified resist composition, and patterning process | ARF5, EIF2B3, KAT5 | TSHR 3649/4885ALDH1A1 4189/4885GAA 1193/4885 |
| US-20200133122-A1 | NOVEL ONIUM SALT, CHEMICALLY AMPLIFIED RESIST COMPOSITION, AND PATTERNING PROCESS | ARF5, ARF4, EIF2B3 | TSHR 3294/4885ALDH1A1 4401/4885GAA 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.